OBJECTIVE: To evaluate the prognostic role of both interim fluorine-18 fludeoxyglucose positron emission tomography (i-(18)F-FDG-PET) and end-of-chemotherapy fluorine-18 fludeoxyglucose positron emission tomography (eoc-(18)F-FDG-PET) in patients with early-stage Hodgkin lymphoma (HL). METHODS: We screened 257 patients with early-stage HL treated with combined modality therapy between March 2003 and July 2011. All were staged using fluorine-18 fludeoxyglucose positron emission tomography ((18)F-FDG-PET) before chemotherapy and after two doxorubicin, bleomycin, vinblastine and dacarbazine cycles (i-(18)F-FDG-PET); 165 patients were also evaluated by (18)F-FDG-PET at the end of chemotherapy (eoc-(18)F-FDG-PET). RESULTS: After revision, 85% of patients were negative for i-(18)F-FDG-PET and 15% were positive. After eoc-(18)F-FDG-PET revision, 23 patients had a positive scan. The median follow-up was 56 months. The 5-year overall survival (OS) and progression-free survival (PFS) for the whole cohort were 97.5% and 95.6%, respectively. For i-(18)F-FDG-PET-negative and i-(18)F-FDG-PET-positive patients, the 5-year PFS rates were 98% and 84%, respectively; for eoc-(18)F-FDG-PET-negative and eoc-(18)F-FDG-PET-positive patients, the 5-year PFS rates were 97% and 78%, respectively. Combining the i-(18)F-FDG-PET and eoc-(18)F-FDG-PET results, the 5-year PFS were 97%, 100% and 82% in negative/negative, positive/negative and positive/positive groups, respectively. The 5-year OS rates were 98% and 83% in eoc-(18)F-FDG-PET-negative and eoc-(18)F-FDG-PET-positive patients, respectively; the 5-year OS was 98%, 100% and 83% in negative/negative, positive/negative and positive/positive groups, respectively. CONCLUSION: This study provides additional information on the prognostic role of i-(18)F-FDG-PET and eoc-(18)F-FDG-PET in early-stage HL. As data are accumulating and the clinical scenario is rapidly evolving, we might need to rethink the use of (18)F-FDG-PET as a prognostic marker for early-stage HL in the near future. ADVANCES IN KNOWLEDGE: This study provides additional information on the prognostic role of i-(18)F-FDG-PET and eoc-(18)F-FDG-PET in early-stage HL. On the basis of the present data, we may suggest to use eoc-(18)F-FDG-PET as a strong prognostic marker, especially for patients with i-(18)F-FDG-PET positivity.

Post-ABVD/pre-radiotherapy 18F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: A retrospective analysis on 165 patients / Ciammella, Patrizia*; Filippi, Andrea Riccardo; Simontacchi, Gabriele; Buglione, Michela; Botto, Barbara; Mangoni, Monica; Iotti, Cinzia; Merli, Francesco; Marcheselli, Luigi; Bisi, Gianni; Ricardi, Umberto; Versari, Annibale. - In: BRITISH JOURNAL OF RADIOLOGY. - ISSN 0007-1285. - ELETTRONICO. - 89:(2016), pp. 0-0. [10.1259/bjr.20150983]

Post-ABVD/pre-radiotherapy 18F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: A retrospective analysis on 165 patients

Mangoni, Monica
Membro del Collaboration Group
;
Bisi, Gianni;
2016

Abstract

OBJECTIVE: To evaluate the prognostic role of both interim fluorine-18 fludeoxyglucose positron emission tomography (i-(18)F-FDG-PET) and end-of-chemotherapy fluorine-18 fludeoxyglucose positron emission tomography (eoc-(18)F-FDG-PET) in patients with early-stage Hodgkin lymphoma (HL). METHODS: We screened 257 patients with early-stage HL treated with combined modality therapy between March 2003 and July 2011. All were staged using fluorine-18 fludeoxyglucose positron emission tomography ((18)F-FDG-PET) before chemotherapy and after two doxorubicin, bleomycin, vinblastine and dacarbazine cycles (i-(18)F-FDG-PET); 165 patients were also evaluated by (18)F-FDG-PET at the end of chemotherapy (eoc-(18)F-FDG-PET). RESULTS: After revision, 85% of patients were negative for i-(18)F-FDG-PET and 15% were positive. After eoc-(18)F-FDG-PET revision, 23 patients had a positive scan. The median follow-up was 56 months. The 5-year overall survival (OS) and progression-free survival (PFS) for the whole cohort were 97.5% and 95.6%, respectively. For i-(18)F-FDG-PET-negative and i-(18)F-FDG-PET-positive patients, the 5-year PFS rates were 98% and 84%, respectively; for eoc-(18)F-FDG-PET-negative and eoc-(18)F-FDG-PET-positive patients, the 5-year PFS rates were 97% and 78%, respectively. Combining the i-(18)F-FDG-PET and eoc-(18)F-FDG-PET results, the 5-year PFS were 97%, 100% and 82% in negative/negative, positive/negative and positive/positive groups, respectively. The 5-year OS rates were 98% and 83% in eoc-(18)F-FDG-PET-negative and eoc-(18)F-FDG-PET-positive patients, respectively; the 5-year OS was 98%, 100% and 83% in negative/negative, positive/negative and positive/positive groups, respectively. CONCLUSION: This study provides additional information on the prognostic role of i-(18)F-FDG-PET and eoc-(18)F-FDG-PET in early-stage HL. As data are accumulating and the clinical scenario is rapidly evolving, we might need to rethink the use of (18)F-FDG-PET as a prognostic marker for early-stage HL in the near future. ADVANCES IN KNOWLEDGE: This study provides additional information on the prognostic role of i-(18)F-FDG-PET and eoc-(18)F-FDG-PET in early-stage HL. On the basis of the present data, we may suggest to use eoc-(18)F-FDG-PET as a strong prognostic marker, especially for patients with i-(18)F-FDG-PET positivity.
2016
89
0
0
Ciammella, Patrizia*; Filippi, Andrea Riccardo; Simontacchi, Gabriele; Buglione, Michela; Botto, Barbara; Mangoni, Monica; Iotti, Cinzia; Merli, Franc...espandi
File in questo prodotto:
File Dimensione Formato  
bjr.20150983.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 783.89 kB
Formato Adobe PDF
783.89 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1121231
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 10
social impact